Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 425-434

  Gersemann, Michael ^a,b   Becker, Svetlana ^b   Nuding, Sabine ^b   Antoni, Lena ^b   Ott, German ^a   Fritz, Peter ^a   Oue, Naohide ^c   Yasui, Wataru ^c   Wehkamp, Jan ^a,b   Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Defensins; Inflammatory bowel disease; Intestinal stem cell marker; Mucins; Mucus; Olfactomedin 4

Indexed keywords

DEFENSIN; DEFENSIN HBD1-3; DIBENZAZEPINE DERIVATIVE; GLYCOPROTEIN; HATH1 PROTEIN; INTERLEUKIN 22; INTERLEUKIN 8; MESSENGER RNA; MUCIN 1; MUCIN 2; OLFACTOMEDIN 4; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BACTEROIDES VULGATUS; CONTROLLED STUDY; DOT HYBRIDIZATION; ENTERITIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; ULCERATIVE COLITIS; UPREGULATION;

CELL CULTURE TECHNIQUES; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MUCUS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS;

EID: 84860168409     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.09.013     Document Type: Article

References (47)

1. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
2. Schreiber S., Rosenstiel P., Albrecht M., Hampe J., Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005, 6:376-388.
3. Gersemann M., Wehkamp J., Fellermann K., Stange E.F. Crohn's disease-defect in innate defence. World J Gastroenterol 2008, 14:5499-5503.
4. Gersemann M., Stange E.F., Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol 2011, 17:3198-3203.
5. Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005, 43:3380-3389.
6. Johansson M.E., Larsson J.M., Hansson G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011, 108(Suppl. 1):4659-4665.
7. Darfeuille-Michaud A., Neut C., Barnich N., Lederman E., Di Martino P., Desreumaux P., et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998, 115:1405-1413.
8. Moussata D., Goetz M., Gloeckner A., Kerner M., Campbell B., Hoffman A., et al. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011, 60:26-33.
9. Shirazi T., Longman R.J., Corfield A.P., Probert C.S. Mucins and inflammatory bowel disease. Postgrad Med J 2000, 76:473-478.
10. Meyer-Hoffert U., Hornef M.W., Henriques-Normark B., Axelsson L.G., Midtvedt T., Pütsep K., et al. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 2008, 57:764-771.
11. Wehkamp J., Schmid M., Fellermann K., Stange E.F. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005, 77:460-465.
12. Wehkamp J., Schmid M., Stange E.F. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 2007, 23:370-378.
13. Wehkamp J., Harder J., Weichenthal M., Mueller O., Herrlinger K.R., Fellermann K., et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003, 9:215-223.
14. Peyrin-Biroulet L., Beisner J., Wang G., Nuding S., Oommen S.T., Kelly D., et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010, 107:8772-8777.
15. McCormick D.A., Horton L.W., Mee A.S. Mucin depletion in inflammatory bowel disease. J Clin Pathol 1990, 43:143-146.
16. Pullan R.D., Thomas G.A., Rhodes M., Newcombe R.G., Williams G.T., Allen A., et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994, 35:353-359.
17. Gersemann M., Becker S., Kubler I., Koslowski M., Wang G., Herrlinger K.R., et al. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009, 77:84-94.
18. Hanski C., Born M., Foss H.D., Marowski B., Mansmann U., Arastéh K., et al. Defective post-transcriptional processing of MUC2 mucin in ulcerative colitis and in Crohn's disease increases detectability of the MUC2 protein core. J Pathol 1999, 188:304-311.
19. Moehle C., Ackermann N., Langmann T., Aslanidis C., Kel A., Kel-Margoulis O., et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med 2006, 84:1055-1066.
20. Tytgat K.M., van der Wal J.W., Einerhand A.W., Büller H.A., Dekker J. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem Biophys Res Commun 1996, 224:397-405.
21. Van Klinken B.J., van der Wal J.W., Einerhand A.W., Büller H.A., Dekker J. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut 1999, 44:387-393.
22. Liu W., Zhu J., Cao L., Rodgers G.P. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology 2007, 51:157-165.
23. Zhang J., Liu W.L., Tang D.C., Chen L., Wang M., Pack S.D., et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 2002, 283:83-93.
24. Zhang X., Huang Q., Yang Z., Li Y., Li C.Y. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004, 64:2474-2481.
25. Grover P.K., Hardingham J.E., Cummins A.G. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev 2010, 29:761-775.
26. Liu W., Chen L., Zhu J., Rodgers G.P. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res 2006, 312:1785-1797.
27. Liu W., Yan M., Liu Y., Wang R., Li C., Deng C., et al. Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Proc Natl Acad Sci U S A 2010, 107:11056-11061.
28. Mannick E.E., Schurr J.R., Zapata A., Lentz J.J., Gastanaduy M., Cote R.L., et al. Gene expression in gastric biopsies from patients infected with Helicobacter pylori. Scand J Gastroenterol 2004, 39:1192-1200.
29. Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
30. van der Flier L.G., Haegebarth A., Stange D.E., van de Wetering M., Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 2009, 137:15-17.
31. Shinozaki S., Nakamura T., Iimura M., Kato Y., Iizuka B., Kobayashi M., et al. Upregulation of Reg 1alpha and GW112 in the epithelium of inflamed colonic mucosa. Gut 2001, 48:623-629.
32. Stange E.F., Travis S.P., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
33. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
34. Stoscheck C.M. Quantitation of protein. Methods Enzymol 1990, 182:50-68.
35. Oue N., Sentani K., Noguchi T., Ohara S., Sakamoto N., Hayashi T., et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 2009, 125:2383-2392.
36. Schmid M., Fellermann K., Fritz P., Wiedow O., Stange E.F., Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007, 81:907-915.
37. Nuding S., Fellermann K., Wehkamp J., Mueller H.A., Stange E.F. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods 2006, 65:335-345.
38. Schlee M., Harder J., Koten B., Stange E.F., Wehkamp J., Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008, 151:528-535.
39. Serafini E.P., Kirk A.P., Chambers T.J. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut 1981, 22:648-652.
40. Bal R.S., Anholt R.R. Formation of the extracellular mucous matrix of olfactory neuroepithelium: identification of partially glycosylated and nonglycosylated precursors of olfactomedin. Biochemistry 1993, 32:1047-1053.
41. Snyder D.A., Rivers A.M., Yokoe H., Menco B.P., Anholt R.R. Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry 1991, 30:9143-9153.
42. Yokoe H., Anholt R.R. Molecular cloning of olfactomedin, an extracellular matrix protein specific to olfactory neuroepithelium. Proc Natl Acad Sci U S A 1993, 90:4655-4659.
43. Silverberg M.S., Cho J.H., Rioux J.D., McGovern D.P., Wu J., Annese V., et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009, 41:216-220.
44. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
45. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
46. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
47. Rodilla V., Villanueva A., Obrador-Hevia A., Robert-Moreno A., Fernández-Majada V., Grilli A., et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A 2009, 106:6315-6320.